CIR "Insufficient Data" Ingredients Subject Of Upcoming FDA Warning Letters
This article was originally published in The Rose Sheet
Executive Summary
FDA is establishing a system to send warning letters to manufacturers using ingredients the Cosmetic Ingredient Review panel has determined do not have sufficient data to establish safety.